Scarica l'app Stockscreener
0.00
100.00%
-53.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$53.01
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$2.76B
Reddito:
$285.01M
Utile/perdita netta:
$95.63M
Rapporto P/E:
0.00
EPS:
1.762
Flusso di cassa netto:
$105.42M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Nome
Soleno Therapeutics Inc
Settore
Industria
Telefono
650-213-8444
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
0.00 | 2.76B | 285.01M | 95.63M | 105.42M | 1.762 |
VRTX
Vertex Pharmaceuticals Inc
|
436.80 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.44 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.11 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.33 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.68 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-10-07 | Iniziato | Goldman | Buy |
| 2025-08-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-23 | Iniziato | TD Cowen | Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2024-12-02 | Reiterato | Robert W. Baird | Outperform |
| 2024-12-02 | Reiterato | Stifel | Buy |
| 2024-09-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-05 | Iniziato | Piper Sandler | Overweight |
| 2024-01-23 | Iniziato | Stifel | Buy |
| 2023-11-21 | Ripresa | Guggenheim | Buy |
| 2020-09-29 | Iniziato | Guggenheim | Buy |
| 2020-01-10 | Iniziato | Craig Hallum | Buy |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2018-02-13 | Reiterato | Maxim Group | Buy |
Mostra tutto
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger - Stock Titan
News On Soleno Therapeutics Inc. (SLNO) Now Under NBIX - Moomoo
Soleno Therapeutics, Inc.(NasdaqGM: ) dropped from Russell 3000E Index - marketscreener.com
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Merger cashes out Soleno (NASDAQ: SLNO) officer equity at $53 - Stock Titan
Soleno Therapeutics (SLNO) director’s shares and options cancelled for $53 cash in Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director equity canceled in $53-per-share merger - Stock Titan
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price - Stock Titan
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share - Stock Titan
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger - Stock Titan
Soleno (SLNO) SVP exits equity as merger pays $53 per share - Stock Titan
Soleno Therapeutics (SLNO) insider equity cashed out at $53 in Neocrine merger - Stock Titan
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes - Stock Titan
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes - Stock Titan
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com Nigeria
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) Nasdaq submits Form 25 to remove common stock - Stock Titan
Soleno Therapeutics, Inc. Announces Resignation of Anish Bhatnagar, M.D. as Chief Executive Officer, Effective May 18, 2026 - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan
Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan
Press Release: Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Moomoo
Soleno Therapeutics, Inc. (SLNO) Stock Report: A Biotech Player with Steady ROE and Strategic Focus on Rare Diseases - DirectorsTalk Interviews
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) dropped from S&P Global BMI Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) dropped from S&P TMI Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqGM: SLNO) dropped from NASDAQ Composite Index - marketscreener.com
The Technical Signals Behind (SLNO) That Institutions Follow - Stock Traders Daily
T. Rowe Price (NASDAQ: SLNO) reports 1,025,868 shares, 2.0% stake - Stock Titan
Avoro and Aghazadeh report 4.45% stake in Soleno (NASDAQ: SLNO) - Stock Titan
Wellington affiliates disclose 8.57% stake in Soleno Therapeutics (SLNO) - Stock Titan
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
State Street (SLNO) holds 2.68M shares, 5.2% stake in Soleno Therapeutics - Stock Titan
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch DisruptionsHagens Berman - PR Newswire
Soleno Therapeutics faces final earnings test before buyout By Investing.com - Investing.com South Africa
Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Soleno Therapeutics Inc Azioni (SLNO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Huang Michael F. | Sr. VP of Clinical Development |
Mar 27 '26 |
Sale |
30.44 |
6,582 |
200,365 |
39,823 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):